首页> 外文期刊>Journal of the American College of Cardiology >Effect of intensive versus moderate lipid-lowering therapy on epicardial adipose tissue in hyperlipidemic post-menopausal women: A substudy of the belles trial (beyond endorsed lipid lowering with ebt scanning)
【24h】

Effect of intensive versus moderate lipid-lowering therapy on epicardial adipose tissue in hyperlipidemic post-menopausal women: A substudy of the belles trial (beyond endorsed lipid lowering with ebt scanning)

机译:在绝经后的高脂血症女性中,强化降脂疗法与中等降脂疗法对心外膜脂肪组织的影响:一项Belles试验的子研究(除了通过ebt扫描支持的降低血脂)

获取原文
获取原文并翻译 | 示例
           

摘要

Objectives: This study sought to evaluate the effect of intensive and moderate statin therapy on epicardial adipose tissue (EAT). Background: EAT has been associated with coronary artery disease severity and outcome. It is currently unknown whether EAT volume changes over time when patients are exposed to statin therapy. Methods: Subanalysis of a randomized study of atorvastatin 80 mg/day versus pravastatin 40 mg/day for 1 year in a clinical trial designed to assess the progression of coronary artery calcium (CAC) in hyperlipidemic post-menopausal women. Patients underwent cardiac computed tomography scans at the start and end of the trial period. Results: Of 420 patients, 194 received atorvastatin and 226 pravastatin; the median low-density lipoprotein change was -53.3% and -28.3% with atorvastatin and pravastatin, respectively (p < 0.001). Baseline EAT correlated with age, body mass index, hypertension, diabetes mellitus, high-density lipoprotein, triglyceride levels, and CAC (p < 0.001). At the end of follow-up, EAT regressed more in the atorvastatin than in the pravastatin group (median, -3.38% vs. -0.83%, p = 0.025). The EAT percent change from baseline was significant in the atorvastatin, but not the pravastatin group (p < 0.001 and p = 0.2, respectively). There was no correlation between lipid lowering and EAT regression. CAC progressed significantly in both groups from baseline. Conclusions: In hyperlipidemic post-menopausal women, statin therapy induced EAT regression, although intensive therapy was more effective than moderate-intensity therapy. This effect does not seem linked to low-density lipoprotein lowering and may be secondary to other actions of statins such as anti-inflammatory effects.
机译:目的:本研究旨在评估强化和中度他汀类药物治疗对心外膜脂肪组织(EAT)的影响。背景:饮食与冠心病的严重程度和预后相关。目前尚不清楚当患者接受他汀类药物治疗时,EAT量是否会随时间变化。方法:在一项旨在评估绝经后高脂血症女性冠状动脉钙(CAC)进展的临床试验中,对1年阿托伐他汀80毫克/天与普伐他汀40毫克/天的随机研究进行了亚组分析。在试验期的开始和结束时对患者进行心脏计算机断层扫描。结果:420例患者中,有194例接受了阿托伐他汀和226例普伐他汀;阿托伐他汀和普伐他汀的低密度脂蛋白变化的中位数分别为-53.3%和-28.3%(p <0.001)。基线EAT与年龄,体重指数,高血压,糖尿病,高密度脂蛋白,甘油三酸酯水平和CAC相关(p <0.001)。随访结束时,阿托伐他汀组的饮食消退高于普伐他汀组(中位数,-3.38%对-0.83%,p = 0.025)。阿托伐他汀组与基线相比的EAT百分比变化显着,普伐他汀组无显着变化(分别为p <0.001和p = 0.2)。降脂与EAT消退之间没有相关性。两组的CAC均从基线显着进展。结论:在绝经后高脂血症妇女中,他汀类药物疗法可导致EAT消退,尽管强化疗法比中等强度疗法更有效。这种作用似乎与低密度脂蛋白的降低没有关系,可能是他汀类药物的其他作用(例如抗炎作用)的继发作用。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号